Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rank in Stocks #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Share Price
$0.12164306
Last synced: 2024-11-11
Market Cap
$38.53M
Change (1 day)
-4.14%
Change (1 year)
0.00%
Country
AU
Trade PharmAust Limited (PAA)

Category

Stock price history for PharmAust Limited (PAA)
Highest end of day price: $0.12 on 2024-11-01

Lowest end of day price: $3.11 on 2001-10-01
Stock price history of PharmAust Limited from 2001 to 2026
Annual Stock Price Performance
Year Performance
2024 72.79%
2023 61.50%
2022 -33.17%
2021 -20.54%
2020 20.68%
2019 171.67%
2018 -30.35%
2017 4.90%
2016 -29.98%
2015 -55.93%
2014 -33.04%
2013 25.44%
2012 -54.31%
2011 -8.75%
2010 -46.71%
2009 152.12%
2008 -65.75%
2007 -55.38%
2006 -27.70%
2005 -34.70%
2004 20.98%
2003 69.43%
2002 -28.84%
2001 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$546.34 38.54%
US
$1.03K 56.45%
NL
$120.74 -14.98%
AU
$140.69 423.19%
US
$764.21 7.37%
CH